Core Viewpoint - WuXi AppTec (603259.SH) has completed a block trade selling shares of its associate WuXi AppTec (2268.HK) for approximately HKD 2.346 billion, marking the fourth sale of its shares this year, which has contributed a total of RMB 4.351 billion to the company's net profit [1][2]. Group 1 - On October 8, WuXi AppTec sold 30.3 million shares of WuXi AppTec, representing 2.47% of the latter's total share capital [2]. - The net investment gain from this sale is expected to impact the company's after-tax net profit for the fiscal year 2025 by approximately RMB 1.679 billion, accounting for over 10% of the latest audited net profit attributable to shareholders for the fiscal year 2024 [2]. - This divestment aligns with a previously authorized strategy from a shareholder meeting on September 23, allowing the investment department to dispose of listed domestic and foreign stocks when market conditions are favorable, with a total limit of 15% of net assets attributable to shareholders [2][3]. Group 2 - WuXi AppTec has strategically timed its stock sales, having previously sold a total of 137 million shares of WuXi AppTec this year, generating approximately HKD 4.604 billion, bringing the total cash realized to nearly HKD 7 billion, significantly boosting the company's profit performance [2]. - The proceeds from this sale will be reinvested into global capacity expansion and capability building, enhancing its integrated CRDMO business model, and attracting top-tier research talent to support long-term growth [3]. - As of October 10, WuXi AppTec's stock closed at RMB 104.72 per share, reflecting a year-to-date increase of 95.02%, while WuXi AppTec's stock closed at HKD 71.85 per share, with a year-to-date increase of 134.42% [3].
药明康德再度“瘦身”:四度减持药明合联,累计变现70亿港元,投资收益对今年净利润贡献逾43亿元